PHGE earnings analysis
What we found in PHGE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing does not provide revenue, margin, EPS, segment, balance-sheet, or cash-flow results needed to assess operating trends against the prior period or prior year. Liquidity was supplemented by approximately $2.4 million of ATM proceeds from 8,902,611 shares issued after quarter-end, but the financing is substantially dilutive. The most material developments are ineffective disclosure controls as of June 30, 2026, continued capital deficiency and NYSE American delisting risk, and the expected APT Chapter 7 filing alongside BiomX Ltd.’s insolvency.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- NYSE compliance plan accepted
- The NYSE American accepted the Company’s compliance plan on June 10, 2026, providing a plan period through September 25, 2027.
- Additional capital raised
- The Company sold 8,902,611 shares under its at-the-market program from July 1 through August 12, 2026, generating approximately $2.4 million in net proceeds.
- Quarterly ATM proceeds
- During the second quarter of 2026, the Company sold 793,005 shares under its at-the-market program for approximately $0.3 million in net proceeds.
- Credit line secured
- The Company issued a five-year warrant to purchase up to 2,000,000 shares at an exercise price of $12.00 per share in connection with the May 13, 2026 line of credit agreement.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ineffective disclosure controls
- Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, and stated that it intends to consult third-party consultants regarding remedial measures.
- Delisting risk
- The Company reported a stockholders’ deficit of $(1.3) million as of December 31, 2025 and remains subject to NYSE American compliance requirements; failure to regain compliance by September 25, 2027 could lead to delisting.
- Severe equity dilution
- The Company sold 8,902,611 shares for approximately $2.4 million from July 1 through August 12, 2026, after selling 793,005 shares for approximately $0.3 million in the second quarter; continued ATM issuance is substantially dilutive.
- Former subsidiary insolvency
- BiomX Ltd. entered insolvency proceedings on December 16, 2025, and the consolidated balance sheet includes approximately $1.3 million due to BiomX Israel that may become subject to trustee claims.
- APT bankruptcy and litigation
- APT is being wound down and is expected to file for Chapter 7 bankruptcy shortly after the filing date; an Emmes action seeks approximately $333,000 for legacy clinical-trial services.
- Potential asset deconsolidation
- The Company expects to deconsolidate APT after commencement of its Chapter 7 case, while the amount and outcome of the approximately $333,000 Emmes claim remain disputed.
What they said about what is next.
The filing provides no quantitative revenue or EPS guidance; no updated operating outlook was disclosed.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 20, 2026
- BiomX Inc. faced significant financial struggles in Q1 2026, posting a net loss of $19.1 million compared to a loss of $7.7 million in Q1 2025. The company's transition to a new strategic focus on defense technologies…
- 10-K · April 30, 2026
- BiomX Inc. has outlined a 12-month agreement with Israel Railways for AI-powered animal detection stations, following a successful pilot. The company reported a continued lack of revenue, with Q4 FY2025 showing a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PHGE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever